Scarica l'app Stockscreener
24.21
0.41%
0.10
Dopo l'orario di chiusura:
24.21
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Precedente Chiudi:
$24.11
Aprire:
$23.95
Volume 24 ore:
187.69K
Relative Volume:
0.48
Capitalizzazione di mercato:
$734.29M
Reddito:
$339.92M
Utile/perdita netta:
$-12.83M
Rapporto P/E:
-56.37
EPS:
-0.4295
Flusso di cassa netto:
$4.52M
1 W Prestazione:
-0.45%
1M Prestazione:
+15.23%
6M Prestazione:
-39.58%
1 anno Prestazione:
+19.26%
Intervallo 1D:
$23.60
$24.55
Intervallo di 1 settimana:
$23.36
$24.98
Portata 52W:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Nome
Castle Biosciences Inc
Settore
Industria
Telefono
866-788-9007
Indirizzo
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, NTRA, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
24.21 | 723.37M | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
517.60 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
193.62 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
564.98 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
283.80 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
WAT
Waters Corp
|
378.89 | 36.82B | 3.77B | 449.25M | 240.68M | 7.8556 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-04-30 | Iniziato | Lake Street | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | BTIG Research | Buy |
| 2019-08-19 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-19 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Form 144 Castle Biosciences For: 1 July By Investing.com - Investing.com Canada
Maetzold family Rule 144 sales reported for CSTL (CSTL) — multiple small lots - Stock Titan
Castle Biosciences updates its melanoma test data, shares in biotech focus - AD HOC NEWS
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down - Yahoo Finance
Castle Biosciences (CSTL) Study Highlights Advancements in Melan - GuruFocus
Castle Biosciences Inc (CSTL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL) - TradingView
Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool - Investing.com
Castle Biosciences’ melanoma test outperforms risk tool By Investing.com - Investing.com UK
Enterprise value to EBIT forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy - norfolkneradio.com
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily
CSTL Forecast — Price Target — Prediction for 2027 - TradingView
Roth Capital Initiates Castle Biosciences at Buy - Moomoo
CSTL Initiated by Roth Capital -- Price Target Announced at $40. - GuruFocus
Price to earnings forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to EBITDA forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to revenue forward of Castle Biosciences, Inc. – TRADEGATE:086 - TradingView
Castle Biosciences (CSTL) Receives Buy Rating and $40 Target fro - GuruFocus
Enterprise value to EBIT forward of Castle Biosciences, Inc. – TRADEGATE:086 - TradingView
Castle Biosciences prioritizes people across patients, clinicians, and employees - Traders Union
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal - Sahm
Castle Biosciences CFO receives Houston business award By Investing.com - Investing.com South Africa
Castle Biosciences CFO Frank Stokes Named Houston Business Journal CFO Awards Honoree - citybiz
Castle Biosciences CFO receives Houston business award - Investing.com
Castle Biosciences CFO Frank Stokes named among 22 Houston finance leaders - Stock Titan
CSTL Q1 2026 Earnings: Narrowly Exceeds EPS Estimates, Stock Edges HigherRetail Earnings Report - dars.gov.et
Castle Biosciences Inc (CSTL) Institutional Confidence - TradingKey
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Castle Biosciences (CSTL) COO sells 8,587 shares, retains over 127K - Stock Titan
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Castle Biosciences Inc (CSTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Castle Biosciences Inc (CSTL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Castle Biosciences president & CEO Derek J. Maetzold sells $86,193 stock - Investing.com Nigeria
Castle Biosciences (CSTL) CEO Maetzold exercises options, trusts sell 4,172 shares - Stock Titan
CSTL (NASDAQ) Rule 144 notice: director sale notice for 4,152 shares - Stock Titan
Castle Biosciences (CSTL) Surpasses 100,000 TissueCypher Test Or - GuruFocus
Castle Biosciences TissueCypher clinical test orders surpass 100,000 milestone - Traders Union
Castle Biosciences’ Barrett’s esophagus test reaches 100k orders By Investing.com - Investing.com Nigeria
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus - StreetInsider
Castle Biosciences’ Barrett’s esophagus test reaches 100k orders - Investing.com
Technical Reactions to CSTL Trends in Macro Strategies - Stock Traders Daily
Castle Biosciences (CSTL) Slips Slightly as Shares Test Near-Term SupportPrice Action Signals - newsline.com
CSTL Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineGrowth Acceleration Report - newsline.com
How The Castle Biosciences (CSTL) Investment Story Is Evolving Without Fresh Analyst Commentary - Yahoo Finance
Earnings call transcript: Castle Biosciences Q1 2026 sees revenue growth - Investing.com
Castle Biosciences Q1 2026 slides: revenue beats, guidance raised - Investing.com
Castle Biosciences Inc Azioni (CSTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Castle Biosciences Inc Azioni (CSTL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Oelschlager Kristen M | Chief Operating Officer |
Jun 16 '26 |
Sale |
20.71 |
8,587 |
177,837 |
30,460 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jun 15 '26 |
Option Exercise |
2.39 |
550 |
1,314 |
22,029 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jun 15 '26 |
Sale |
20.66 |
3,622 |
74,831 |
12,646 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jun 15 '26 |
Sale |
20.66 |
550 |
11,363 |
21,479 |
1.05%
2.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):